Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
Would you clear a patient who completed treatment for breast DCIS to donate her kidney to her husband?
Germline genetic testing negative
Answer from: Medical Oncologist at Community Practice
Yes.
Sign in or Register to read more
6634
Related Questions
Would you offer endocrine therapy to a patient with T1c tumor who was initially ER+ (15%)/PR negative/HER2-1+ but changed to a triple negative phenotype after neoadjuvant chemotherapy with TC?
Is there a role for systemic therapy in recurrent oligometastatic triple negative breast cancer with brain only disease?
How would you discuss the prognosis of HR-positive early breast cancer in an elderly >90 patient who elects against surgery in favor of endocrine treatment only?
How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
Would you offer local therapy with either SBRT or Y-90 in a patient with metastatic ER+ HER2 low breast cancer with two oligometastatic liver lesions currently on AI + CDK4/6 inhibitor?
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
Would you give adjuvant chemotherapy to a premenopausal female who underwent bilateral mastectomies for ER+ pT2N1 disease, grade 1, with low oncotype (5)?
For which patients, if any, do you typically order additional imaging workup for staging in early-stage breast cancer?
What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?